CRISP-AMI: No role for counterpulsation in non-shock STEMI

Although door-to-balloon times have declined over the last few years, mortality rates from acute ST-elevation myocardial infarction (STEMI) have not improved.  One proposed method to counteract this has been the routine use of intra-aortic balloon counter pulsation (IABC) during primary PCI; animal studies have suggested a reduction in infarct size, and a possible clinical benefit […]

Read More…

ATOLL: enoxaparin improves STEMI outcomes

Primary Percutaneous Coronary Intervention (PPCI) has traditionally been performed with the use of boluses of unfractionated heparin administered throughout the procedure.  The use of newer agents, such as enoxaparin administered intravenously throughout the procedure, has not previously been compared to this standard of therapy. […]

Read More…

Kidney disease triples bleeding risk post PCI

The need for dual antiplatelet therapy following percutaneous coronary intervention (PCI) also imposes a significant bleeding risk. Chronic kidney disease (CKD) is associated with poorer outcomes following PCI, and in addition a detrimental effect on platelet function is well described. In this study the authors investigated the outcomes of patients with chronic renal impairment (defined […]

Read More…